Caliway’s drug molecule CBL-514 to treat Dercum’s disease receives EMA orphan drug designation: New Taipei City Thursday, November 14, 2024, 16:00 Hrs [IST] Caliway Biopharmac ...
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...
In a similar manner, member states must now pool their resources to address their shared geoeconomic concerns. To achieve ...
Product development highlights Alvotech announced that the European Medicines Agency (EMA) accepted a Marketing Authorization ...
Continuing to advance the pipeline and remain on-track to engage with the FDA on TP-04 (Papulopustular Rosacea) and TP-05 ...
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...
TORONTO and HAIFA, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) -- . (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based ...
Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...
Cardiol’s broad IP portfolio and regulatory pathway focus, including FDA and European Medicines Agency orphan designations, ...
Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced todayPivotal Phase 3 trial of mavorixafor in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback